Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009.
暂无分享,去创建一个
S. Fosså | R. Huddart | P. Warde | D. Bolton | T. Gilligan | A. Heidenreich | D. Bolton | S. Fosså | A. Heidenreich | P. Warde | S Fossa | S. Fosså | Axel Heidenreich | Damien M Bolton | R. Huddart | Timothy D. Gilligan
[1] R. Huddart,et al. Canadian consensus guidelines for the management of testicular germ cell cancer. , 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.
[2] D. Dearnaley,et al. Surveillance in stage I seminoma patients: a long-term assessment. , 2010, European urology.
[3] P. Warde,et al. No role for routine chest radiography in stage I seminoma surveillance. , 2010, European urology.
[4] A. Horwich,et al. Testicular seminoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] D. Dearnaley,et al. Treating IIA/B seminoma with combination carboplatin and radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Dearnaley,et al. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. , 2009, Clinical radiology.
[7] H. Amthauer,et al. [18F]-FDG-PET in clinical stage I/II non-seminomatous germ cell tumours: results of the German multicentre trial. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] D. Dearnaley,et al. Evidence-based pragmatic guidelines for the follow-up of testicular cancer: optimising the detection of relapse , 2008, British Journal of Cancer.
[9] G. Mead,et al. Relapse patterns in 2,466 stage 1 seminoma patients (pts) entered into Medical Research Council randomised trials , 2008 .
[10] S. Fosså,et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. , 2008, European urology.
[11] U. Schneider,et al. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. , 2008, International journal of radiation oncology, biology, physics.
[12] W. Brenner,et al. The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminoma. , 2008, The Journal of urology.
[13] M. Louwman,et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Warde,et al. Evidence‐based guidelines for following stage 1 seminoma , 2007, Cancer.
[15] P. Abrams,et al. Evidence--based medicine overview of the main steps for developing and grading guideline recommendations. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[16] P. Hall,et al. Noncancer causes of death in survivors of testicular cancer. , 2007, Journal of the National Cancer Institute.
[17] G. Horan,et al. CT Chest is a Waste of Resources in the Staging of Seminoma of the Testis , 2007 .
[18] S. Fosså,et al. Late relapses of germ cell malignancies: incidence, management, and prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] F. V. van Leeuwen,et al. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Carles,et al. Risk-adapted management for patients with clinical stage I seminoma: the Second Spanish Germ Cell Cancer Cooperative Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] John D Boice,et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. , 2005, Journal of the National Cancer Institute.
[22] G. Rustin,et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial , 2005, The Lancet.
[23] A. Sigurdson,et al. International patterns and trends in testis cancer incidence , 2005, International journal of cancer.
[24] C. Catton,et al. Should surveillance be considered the standard of care in stage I seminoma , 2005 .
[25] C. Bokemeyer,et al. FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals. , 2005, European journal of radiology.
[26] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[27] S. Fosså,et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment of stage I Testicular Seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Catton,et al. Stage II testicular seminoma: patterns of recurrence and outcome of treatment. , 2004, European urology.
[29] C. Meisner,et al. Para-aortic irradiation for stage I testicular seminoma: results of a prospective study in 675 patients. A trial of the German testicular cancer study group (GTCSG) , 2004, British Journal of Cancer.
[30] G. Mikuz,et al. Handling and reporting of biopsy and surgical specimens of testicular cancer. , 2004, European urology.
[31] Andrew K. Lee,et al. Mortality after cure of testicular seminoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] J. Logue,et al. Short course para-aortic radiation for stage I seminoma of the testis. , 2003, International journal of radiation oncology, biology, physics.
[33] L. Livi,et al. Stage I seminoma of the testis: a bi‐institutional retrospective analysis of patients treated with radiation therapy only , 2003, BJU international.
[34] B. Leibovich,et al. Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity? , 2003, The Journal of urology.
[35] D P Dearnaley,et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] C. Meisner,et al. Radiotherapy for stages IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Daugaard,et al. Surveillance in stage I testicular cancer , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[38] M. Climent,et al. Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: the experience of the Spanish Germ-Cell Cancer Group (GG). , 2002, European urology.
[39] A. Horwich,et al. Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis , 2002 .
[40] A. Pollack,et al. Radiotherapy for stage II testicular seminoma. , 2001, International journal of radiation oncology, biology, physics.
[41] L. Einhorn,et al. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[42] L. Collette,et al. Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. , 1999, Journal of the National Cancer Institute.
[43] S. Fosså,et al. Optimal planning target volume for stage I testicular seminoma: A Medical Research Council randomized trial. Medical Research Council Testicular Tumor Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] R. Miralbell,et al. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[45] A. Horwich,et al. Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party. , 1997, European journal of cancer.
[46] S. Fosså,et al. External beam abdominal radiotherapy in patients with seminoma stage I: field type, testicular dose, and spermatogenesis. , 1997, International journal of radiation oncology, biology, physics.
[47] R. Motzer,et al. Surgery for a post-chemotherapy residual mass in seminoma. , 1997, The Journal of urology.
[48] S. Culine,et al. Optimal management of residual mass after chemotherapy in advanced seminoma: there is time for everything. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] G. Kerr,et al. Radiotherapy for stages I and II testicular seminoma: results and morbidity in 238 patients. , 1995, The British journal of radiology.
[50] A. Stiggelbout,et al. Second cancer risk following testicular cancer: a follow-up study of 1,909 patients. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] W. van Putten,et al. Orchidectomy followed by radiotherapy in 176 stage I and II testicular seminoma patients: benefits of a 10-year follow-up study. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[52] Leslie H. Sobin,et al. TNM Classification of Malignant Tumours, 7th Edition , 2009 .
[53] A. Calvert,et al. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. , 2002, European journal of cancer.
[54] U. Pichlmeier,et al. Adjuvant treatment of clinical stage I seminoma: is a single course of carboplatin sufficient? , 2000, Urology.
[55] R. Coleman,et al. The management and clinical course of testicular seminoma: 15 years' experience at a single institution. , 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).
[56] D. Dearnaley,et al. Residual mass following chemotherapy of seminoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] M. Ro̸rth,et al. Surveillance following orchidectomy for stage I seminoma of the testis. , 1993, European journal of cancer.
[58] S. Kjaer,et al. Survival of Danish cancer patients 1943-1987. Female genital organs. , 1993, APMIS. Supplementum.